Highest-materiality recent filing
STAAR Surgical Q1 net sales up 119.6% to $93.5M; returns to profitability with GAAP EPS $0.10
Record Q1 net sales of $93.5M, up 119.6% YoY, driven by China recovery and U.S. growth.
STAAR Surgical prelim Q1 2026 net sales expected >$90M, up from $42.6M YoY
Net sales expected to exceed $90M in Q1 2026, more than double prior year's $42.6M.
STAAR Surgical appoints interim co-CEOs; reports China stabilization, EVO+ launch, cost cuts
Warren Foust and Deborah Andrews named Interim Co-CEOs after Alcon merger rejected by shareholders in Jan 2026.
STAAR Surgical appoints interim co-CEOs after CEO Farrell steps down; global CEO search launched
Stephen C. Farrell stepped down as CEO effective Jan 31, 2026, per prior cooperation agreement with Broadwood Partners.
STAAR Surgical elects new Board Chair; forms CEO Search Committee
Neal C. Bradsher (Broadwood Capital, largest stockholder) elected Board Chair effective Jan 15, 2026.
STAAR Surgical CEO Farrell to step down Jan 31; Broadwood appoints three new directors
CEO Stephen Farrell to step down as CEO by Jan 31, 2026; will remain as consultant for 1 year at $45k/month.
STAAR Surgical shareholders vote down Alcon merger; deal terminated
Preliminary vote tally failed to secure enough shareholder approval for the Alcon merger at special meeting on Jan 6, 2026.
STAAR Surgical's merger with Alcon terminated after shareholder vote; no fee
Merger agreement with Alcon terminated effective Jan 6, 2026; no termination fee payable.
Alcon raises STAAR Surgical acquisition price to $30.75 per share from $28.00
Merger consideration increased to $30.75/share in cash, up from $28.00/share (approx. 9.8% increase).
STAAR's go-shop period expires with no competing bids; 21 parties contacted, none submitted proposal
Go-shop period expired December 6, 2025; no competing acquisition proposals received.
30-day go-shop period through Dec 6, 2025; STAAR may actively solicit third-party proposals.
STAAR postpones special meeting on Alcon merger to Dec 3 amid ongoing discussions
Special meeting of stockholders postponed from Nov 6 to Dec 3, 2025; new record date: Oct 24, 2025.
STAAR adjourns special meeting on Alcon merger to Nov 6, 2025
Special meeting scheduled for Oct 23, 2025 adjourned to 8:30 a.m. PT on Nov 6, 2025.
STAAR Surgical announces preliminary Q3 net sales $94.7M (+6.9%); includes $25.9M China shipment
Preliminary net sales $94.7M, up 6.9% YoY from $88.6M; outside China grew 7.7%.
STAAR Surgical supplements proxy for Alcon merger; faces lawsuits, Broadwood opposition
Two shareholder lawsuits filed Oct 1 in NY state court alleging proxy misrepresentations; demand letters also received.
STAAR urges stockholders to vote FOR Alcon merger at $28/sh, citing 59% VWAP premium
Alcon merger offers $28.00 per share cash; 51% premium to Aug 4 close, 59% to 90-day VWAP.
Alcon to acquire STAAR Surgical for $28/share in cash, ~$1.5B equity value
Alcon pays $28/share cash, a ~59% premium to STAAR's 90-day VWAP and 51% premium to Aug 4 close.
Deborah Andrews appointed CFO effective June 25, 2025; she served as interim CFO since March 2025 and previously held the role from 2007-2013 and 2017-2020.
STAAR Surgical announces $30M buyback and China NMPA approval for EVO+ TICL
Authorized $30M share repurchase program, expected to run over six months from cash on hand.
STAAR Surgical Q1 revenue plunges 45%, swings to $54.2M loss; withdraws outlook
Net sales $42.6M, down 45% YoY; net loss $54.2M ($1.10) vs $3.3M loss prior year.
Louis Silverman reappointed to board effective April 24, 2025; board expands to 7 members.
STAAR Surgical realigns leadership: CFO steps down, new President & COO named
Warren Foust promoted to President & COO; Magda Michna named Chief Development Officer.
STAAR Surgical appoints Stephen Farrell CEO, replacing Tom Frinzi; Board chair changed
Stephen Farrell named President & CEO effective Feb 26, 2025, succeeding Thomas Frinzi at Board's request.
STAAR Surgical reports Q3 net sales up 10% to $88.6M; revises 2024 regional growth assumptions
Net income of $10.0M ($0.20 EPS) vs $4.8M ($0.10 EPS) a year ago; adjusted EBITDA $16.2M.
STAAR Surgical Q3 net sales up 10% to $88.6M; FY China growth outlook halved to 2%
Net sales $88.6M (+10% YoY); net income $10.0M ($0.20 EPS) vs $4.8M ($0.10) prior year.
STAAR Surgical Q2 net sales $99.0M (record), EPS $0.15, raises FY2024 guidance
Record Q2 net sales of $99.0M (up 7% YoY); constant currency $100.4M (+9%).
STAAR Surgical Q1 net sales up 5% to $77.4M; net loss $0.07ps; raises FY24 EBITDA outlook
Net sales $77.4M (+5% YoY; +7% constant currency); ICL sales +9% on +2% units.
STAAR Surgical preliminary Q1 net sales >$77M; record US ICL sales of $5M, up 20% sequentially
Preliminary Q1 2024 net sales in excess of $77M; US ICL sales hit record $5M, up ~20% sequentially.
STAAR Surgical Q4 net sales up 19% to $76.3M; ICL sales +22%; FY2024 outlook $335-340M
Q4 net sales $76.3M (+19% YoY), ICL sales $74.6M (+22%), ICL units +19%.
STAAR Surgical prelim Q4 net sales ~$76.5M, ICL sales +22%; FY2024 outlook $335-340M
Preliminary FY2023 net sales ~$322.5M (+13% YoY); Q4 net sales ~$76.5M (+19% YoY).
STAAR Surgical amends Investor Day slide: 2026E Adj. EBITDA ex. SBC range raised to $90M-$120M
Adjusted EBITDA ex. SBC for 2026E corrected to $90M-$120M from previously stated $75M-$110M.
On June 25, 2025, STAAR Surgical Company (the “Company”) announced that its Board of Directors (the “Board”) appointed Deborah Andrews as Chief Financial Officer of the Company, effective June 25, 2025 (the “Effective Date”).
Ms. Weisner notified the Company that she has chosen not to stand for re-election when her term expires at the 2025 Annual Meeting
the Company entered into a consulting agreement with Mr. Jiang to serve as a special strategic advisor to the Company’s Asia Pacific business through the end of fiscal 2025, in the temporary role of Chief of APAC Strategy
the Board appointed Louis E. Silverman, who served on the Company’s Board from 2014-2022, as a director, effective April 24, 2025
Patrick Williams has agreed to step down, effective as of the same date, at the request of the Board from his position as Chief Financial Officer.
the Board appointed Magda Michna, PhD, the Company’s Chief Clinical, Regulatory and Medical Affairs Officer, to the newly created role of Chief Development Officer
Keith Holliday, PhD has agreed to retire, effective as of the Effective Date, at the request of the Board from his position as Chief Technology Officer
Mr. Stephen C. Farrell will continue to serve as the Chief Executive Officer of the Company and as a member of the Company’s Board but, effective as of the Effective Date, will no longer hold the title of President of the Company.
the Board appointed Deborah Andrews, the Company’s former Chief Financial Officer, to serve as the Company’s Interim Chief Financial Officer and principal accounting officer on an interim basis, effective as of the Effective Date
the Board appointed the Company’s Chief Operating Officer, Warren Foust, as President and Chief Operating Officer of the Company, effective March 17, 2025
the Board elected Director Elizabeth Yeu, M.D., to serve as Board Chair, effective as of the Effective Date.
the Board appointed Stephen C. Farrell to succeed Thomas G. Frinzi as President and Chief Executive Officer, effective February 26, 2025
Max materiality 0.90 · Median 0.60 · Most common event earnings